cytochrome P450 family 4 subfamily F member 25, pseudogeneGenealiases: []
Q-omics provides the consensus-scored CYP4F25P profile across patient tissues and cancer cell-line models. CYP4F25P expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, CYP4F25P is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, CYP4F25P RNA expression shows 12,666 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SKCM, COAD, and TGCT as cancer lineages where CYP4F25P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYP4F25P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYP4F25P survival associations across molecular data types. CYP4F25P RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYP4F25P RNA expression–survival associations across cancer types. High CYP4F25P expression shows unfavorable associations in THCA, ESCA, PCPG and ACC, but favorable associations in SKCM and BLCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for CYP4F25P RNA expression.
This table summarizes CYP4F25P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CYP4F25P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYP4F25P shows lower tumor expression in COAD, THCA, HNSC, LUAD and BRCA and higher tumor expression in KIRC. The COAD box plot shows higher CYP4F25P RNA expression in normal versus tumor tissue (log2 FC = −0.455, t-test p < 0.001).
This table shows molecular features associated with CYP4F25P in patient tissues and cancer cell lines. In patient samples, CYP4F25P shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
